Saturday, 31 October 2026European Markets

PROACTIS Stock Jumps 21% As Market Outperforms At End Of Wednesday Session

Loading stream...

(vianews) -

about proactis sa

proactis sa is an industry leader when it comes to source-to-pay software solutions that enable businesses to gain better control over their spending. with an expansive platform, this company provides procurement solutions designed to simplify purchasing of routine goods and services, capital goods, and major projects. proactis sa provides services such as invoice capture services, system administration, supplier onboarding, tail spend management services and seamless integration with various erp or financial systems. based in suresnes, france - as a subsidiary of proactis euro hedgeco limited - proactis sa stands out by delivering top quality software solutions designed to optimize procurement processes within businesses.

yearly analysis

according to available data, proactis sa's stock is trading at eur0.05 at present - below its 52-week high of eur0.12 but above its low of eur0.04. this suggests a period of volatility within its past year. investors may wish to take this information into account when assessing a stock's current standing and potential for future growth. furthermore, investors may wish to analyze other metrics, such as financial performance and industry trends in order to gain a fuller picture of the value and returns associated with each stock they own.

technical analysis

proactis sa has been trading below both its 50-day and 200-day moving averages, which indicates a downward trend in price. even though trading volume increased by 59.66% recently, proactis' stock failed to capitalize on this momentum and remains under significant strain. proactis sa's stock has shown increasing levels of volatility over the last week, month and quarter; its intraday variation average ranging from an 8.21% decrease to 10.03% increase respectively over these timespan. last week saw its highest average volatility amplitude at 10.66%; an indicator of high uncertainty regarding price movements of its shares. according to the stochastic oscillator, proactis sa's stock may be overbought (>=80), signalling that a potential correction could come soon. overall, proactis sa stock is currently trading below its moving averages and experiencing high volatility, suggesting overbuying. investors should use caution and closely track its price movements before making any investment decisions.

quarter analysis

over the past twelve months, revenue growth at our company has seen a decline of 3.6% to total 14.11m. this slower-than-average growth could signal challenges with expanding business operations.

equity analysis

as per the provided data, proactis sa has posted negative earnings during its most recent twelve month period, with an eps of eur-0.01 representing negative earnings relative to shareholder's equity. furthermore, its return on equity stood at -3.88% indicating it has not generated substantial returns for shareholders over this timeframe. investors should carefully consider this information prior to making investment decisions.

more news about proactis sa (proac.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com